EMERALD ADVISERS, LLC

Position in KALV — KalVista Pharmaceuticals, Inc.

CIK 1015083 LEOLA, PA

Position in KALV

as of Mar 31, 2026 · filed May 4, 2026 Compact

Position Value

$25,444,782

+$3,795,788 QoQ

Shares Held

1,264,023

-5.7% QoQ

Ownership

2.37%

of shares outstanding

% of Portfolio

0.81%

of 13F equity value

Holder Rank

#17

of 182 holders

Holding Since

Mar 2021

12 quarters on record

Voting authority Sole 76.73918908121134.ToString("F0")% Shared 0.ToString("F0")% None 23.26081091878866.ToString("F0")%

Healthcare · as of Mar 31, 2026

EMERALD ADVISERS, LLC holds $427,347,303 across 25 Biotechnology names. KALV ranks #7 (6.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	COGT	Cogent Biosciences, Inc.	1,588,132	$61,127,200
2	TVTX	Travere Therapeutics, Inc.	1,557,196	$46,264,293
3	BBIO	BridgeBio Pharma, Inc.	515,361	$38,270,707
4	MIRM	Mirum Pharmaceuticals, Inc.	397,263	$36,699,155
5	SYRE	Spyre Therapeutics, Inc.	613,365	$30,938,130
6	NKTR	Nektar Therapeutics	394,604	$28,391,757
7	KALV	KalVista Pharmaceuticals, Inc. This page	1,264,023	$25,444,782
8	TRVI	Trevi Therapeutics, Inc.	1,839,566	$21,946,022

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$25,444,782	1,264,023	-5.7%	Shares	Sole	2026-05-04
2025-12-31	$21,648,994	1,340,495	-0.8%	Shares	Sole	2026-02-09
2025-09-30	$16,458,273	1,351,254	+30.2%	Shares	Sole	2025-10-30
2025-06-30	$11,735,143	1,038,049	+15.6%	Shares	Sole	2025-08-04
2025-03-31	$10,365,112	898,190	+7.4%	Shares	Sole	2025-05-01
2024-12-31	$7,081,343	836,050	+0.0%	Shares	Sole	2025-02-11
2024-09-30	$9,680,741	835,988	+29.8%	Shares	Sole	2024-10-29
2024-06-30	$7,585,106	643,897	-4.1%	Shares	Sole	2024-08-06
2024-03-31	$7,960,147	671,176	+120.7%	Shares	Sole	2024-05-08
2021-09-30	$5,306,771	304,113	-18.8%	Shares	Sole	2021-10-28
2021-06-30	$8,976,206	374,633	-5.7%	Shares	Sole	2021-07-29
2021-03-31	$10,206,200	397,283	—	Shares	Sole	2021-04-29
No filing history on record for this holder in this stock.